Eli Lilly says experimental drug slows decline from Alzheimer’s
If approved, Donanemab has annual multi-billion-dollar sales potential. Lilly shares rose 6% in early-afternoon trading.
Eli Lilly and Co.
Articles
Coming off record fundraising year, Indiana’s life science sector looks for even more capital in 2023
Inventors and entrepreneurs who don’t have a track record face the biggest challenges, a panel of experts said Friday morning at IBJ’s Life Sciences Power Breakfast.
Powerful new obesity drug poised to upend weight-loss care
If approved for weight loss, Eli Lilly’s tirzepatide could become the most effective drug to date in an arsenal of medications that are transforming the treatment of obesity, which affects more than 4 in 10 American adults and is linked to dozens of diseases.
Lilly diabetes drug helps patients shed average of 34 pounds, a development sure to boost sales
The Indianapolis-based drugmaker said it would complete submission of tirzepatide to the U.S. Food and Drug Administration in coming weeks for treatment of obesity and expects regulatory action as early as late 2023.
Lilly to sell off drug for low blood sugar in deal worth up to $1.1B
Worldwide sales of Baqsimi totaled $139.3 million last year, representing less than 1% of Indianapolis-based Lilly’s worldwide revenue of $28.5 billion.
Lilly to invest another $1.6 billion in Boone County site, add 200 jobs
The expansion will bring Eli Lilly and Co.’s total investment in the project to $3.7 billion, the most the company has ever spent on a single manufacturing site.
Lebanon planners approve Eli Lilly manufacturing site in Boone County
The Lebanon Plan Commission voted unanimously Monday to approve Eli Lilly and Co.’s development plan for its two manufacturing facilities in Boone County.
Following Lilly’s lead, Novo Nordisk plans insulin price cuts
Novo Nordisk will start slashing some U.S. insulin prices up to 75% next year, following a path set earlier this month by rival Eli Lilly and Co.
Lilly’s older Alzheimer’s drug fails to prevent disease in trial
Eli Lilly said the study concludes its clinical development of solanezumab, apparently shutting the door on one of the most closely watched experimental drugs over the past decade.
In ninth try, Eli Lilly asks shareholders to end staggered terms for board members
The Weinberg Center for Corporate Governance at the University of Delaware, a leading voice for responsible corporate leadership, has generally supported the elimination of staggered terms, saying they can lead to entrenched boards and management that fails to perform.
Under growing pressure, Lilly to cut price of popular insulins by 70%
The Indianapolis-based drugmaker also said it will expand a program that caps patient out-of-pocket costs at $35 or less a month.
Downtown’s largest employers bet on hybrid work
Cummins, Rolls-Royce, Eli Lilly and Co., AES and Elevance Health are among the city’s largest downtown employers and all say most of their workers have the option of working at home at least part of the time.
Lilly receives FDA approval for rare blood cancer treatment
Jaypirca was approved to treat mantle cell lymphoma, or MCL. a rare blood cancer that starts in white blood cells in the lymph nodes for which there is no cure, according to Lilly. The disease affects about 1 in 200,000 people worldwide each year.
Lilly to invest another $450M in North Carolina factory
The move will create at least 100 new jobs at the plant, located in Research Triangle Park, the largest research park in the country.
Feds reject Lilly’s fast-track application for Alzheimer’s drug
Donanemab’s ability to rapidly remove amyloid beta from patients’ brains prevented the required number of patients from receiving the drug for a full 12 months, Lilly said, resulting in the FDA rejection.
Lilly plans to construct 12 buildings at LEAP campus in Boone County
The company’s more detailed plans for the project reveal the 12 buildings would range in size from a 3,200-square-foot visitors center to a pair of three-story, 330,000-square-foot manufacturing facilities.
California to sue Lilly, other drug companies over insulin prices
California on Thursday announced it will sue the companies that make and promote most of the nation’s insulin, accusing them of scheming to illegally increase the price of the drug.
Stories about Scott Wise, IMS and Lilly are IBJ’s most-read of 2022
The list—based on the number of times readers clicked on stories—includes several other real estate stories as well, including the future plans for Christel DeHaan’s former estate and a fitness chain’s plans to move into a former Marsh store.
With stock trading near record high, Lilly embarks on ambitious 2023
The Indianapolis-based pharmaceutical company is preparing for one of its most ambitious years in memory for 2023, with plans to advance five new drugs into late-stage clinical studies and move four into regulatory review.
Diabetes drug Lilly abandoned has new life
In an amazing resurrection, teplizumab, developed by another company after Lilly trials were a letdown, is one of the hottest new drugs on the market.